New Zealand
Intelligence de marché des dispositifs médicaux pour New Zealand. Changements réglementaires, concurrents et tendances d'achats.
Signaux des 7 derniers jours
Merit Medical enrolled the first patient in its WRAP registry to study the Wrapsody endoprosthesis for dialysis patients.
Fluidx Medical's GPX embolic device successfully treated a complex renal tumour in a clinical trial in New Zealand.
The IN.PACT AV Access trial shows a 52.2% patency rate at 24 months, outperforming Medtronic's PTA at 36.2%.
Medtronic's IN.PACT AV DCB shows superior effectiveness over PTA in ESRD patients after two years, impacting dialysis care.
Merit Medical has enrolled the first patients in the WAVE study for its Wrapsody stent graft for dialysis access.
The IN.PACT AV Access trial shows significant improvements in primary patency for DCB over PTA in hemodialysis patients.
LINC 2021 presented data showing IN.PACT AV DCB outperforms PTA in AVF treatment, with 65.3% primary patency at 1 year.
Debate at CX 2021 revealed split opinions on flow reduction in high-flow fistulas for dialysis patients.
The IN.PACT AV Access trial shows DCB treatment offers longer intervention-free periods for kidney disease patients than PTA.
Fist Assist Devices partners with Regional Health Care Group to launch the FA-1 device in Australia and New Zealand.
Two-year SWING trial data show safety and efficacy of Sundance sirolimus DCB for BTK disease treatment.
AAA-SHAPE trial results on IMPEDE-FX device for AAA management will be presented at VEITH 2023 in NYC.
Gore has enrolled first patients in the VBX FORWARD study comparing VBX stent grafts to bare metal stents for iliac disease.